PMID- 19260778
OWN - NLM
STAT- MEDLINE
DCOM- 20091130
LR  - 20181201
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
VI  - 15
IP  - 8
DP  - 2009 Aug
TI  - A comparison of human bone marrow-derived mesenchymal stem cells and human 
      umbilical cord-derived mesenchymal stromal cells for cartilage tissue 
      engineering.
PG  - 2259-66
LID - 10.1089/ten.tea.2008.0393 [doi]
AB  - Bone marrow-derived mesenchymal stem cells (BMSCs) have long been considered the 
      criterion standard for stem cell sources in musculoskeletal tissue engineering. 
      The true test of a stem cell source is a side-by-side comparison with BMSCs. 
      Human umbilical cord-derived mesenchymal stromal cells (hUCMSCs), one such 
      candidate with high potential, are a fetus-derived stem cell source collected 
      from discarded tissue (Wharton's jelly) after birth. Compared with human BMSCs 
      (hBMSCs), hUCMSCs have the advantages of abundant supply, painless collection, no 
      donor site morbidity, and faster and longer self-renewal in vitro. In this 6-week 
      study, a chondrogenic comparison was conducted of hBMSCs and hUCMSCs in a 
      three-dimensional (3D) scaffold for the first time. Cells were seeded on 
      polyglycolic acid (PGA) scaffolds at 25 M cells/mL and then cultured in identical 
      conditions. Cell proliferation, biosynthesis, and chondrogenic differentiation 
      were assessed at weeks 0, 3, and 6 after seeding. At weeks 3 and 6, hUCMSCs 
      produced more glycosaminoglycans than hBMSCs. At week 6, the hUCMSC group had 
      three times as much collagen as the hBMSC group. Immunohistochemistry revealed 
      the presence of collagen types I and II and aggrecan in both groups, but type II 
      collagen staining was more intense for hBMSCs than hUCMSCs. At week 6, the 
      quantitative reverse transcriptase polymerase chain reaction (RT-PCR) revealed 
      less type I collagen messenger RNA (mRNA) with both cell types, and more type II 
      collagen mRNA with hBMSCs, than at week 3. Therefore, it was concluded that 
      hUCMSCs may be a desirable option for use as a mesenchymal cell source for 
      fibrocartilage tissue engineering, based on abundant type I collagen and aggrecan 
      production of hUCMSCs in a 3D matrix, although further investigation of signals 
      that best promote type II collagen production of hUCMSCs is warranted for hyaline 
      cartilage engineering.
FAU - Wang, Limin
AU  - Wang L
AD  - Department of Biomedical Engineering, University of Michigan , Ann Arbor, 
      Michigan, USA.
FAU - Tran, Ivy
AU  - Tran I
FAU - Seshareddy, Kiran
AU  - Seshareddy K
FAU - Weiss, Mark L
AU  - Weiss ML
FAU - Detamore, Michael S
AU  - Detamore MS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Collagen Type I)
RN  - 0 (Collagen Type II)
RN  - 0 (Glycosaminoglycans)
RN  - 9007-49-2 (DNA)
RN  - RMB44WO89X (Hydroxyproline)
SB  - IM
MH  - Bone Marrow Cells/*cytology
MH  - Cartilage/*physiology
MH  - Collagen Type I/genetics/metabolism
MH  - Collagen Type II/metabolism
MH  - DNA/metabolism
MH  - Gene Expression Regulation
MH  - Glycosaminoglycans/metabolism
MH  - Humans
MH  - Hydroxyproline/metabolism
MH  - Immunohistochemistry
MH  - Mesenchymal Stem Cells/*cytology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Staining and Labeling
MH  - *Tissue Engineering
MH  - Umbilical Cord/*cytology
EDAT- 2009/03/06 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/03/06 09:00
PHST- 2009/03/06 09:00 [entrez]
PHST- 2009/03/06 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.1089/ten.tea.2008.0393 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2009 Aug;15(8):2259-66. doi: 10.1089/ten.tea.2008.0393.